Yan Xixin, Song Yuanlin, Shen Ce, Xu Wenbing, Chen Liangan, Zhang Jian, Liu Huiguo, Huang Mao, Lai Guoxiang, Qian Guishen, Wang Jing, Ye Xianwei, Zheng Jinping, Bai Chunxue
Department of Pulmonary and Critical Care Medicine, Second Hospital Affiliated to Hebei Medical University, Hebei.
Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University; Shanghai Respiratory Research Institute.
Int J Chron Obstruct Pulmon Dis. 2017 Mar 22;12:803-812. doi: 10.2147/COPD.S114423. eCollection 2017.
Airway mucus hypersecretion is a frequent symptom associated with acute and chronic airway disease. Inhibition of mucus production or promotion of mucolysis not only relieved symptoms but also improved disease outcomes. There are numerous available mucoactive medicines for prescription, and how to select them properly for different diseases is important for clinical practice. So far, there is no one consensus or guideline reported. A group of Chinese pulmonary physicians worked together to complete this consensus based on literature review, summarized mechanism and usage of each classical mucoactive medicine. In general, antioxidant mucoactive medicines play an important role in chronic airway disease, including but not limited to airway mucus clearance, reduced acute exacerbation and improved pulmonary function.
气道黏液高分泌是急慢性气道疾病常见的症状。抑制黏液产生或促进黏液溶解不仅能缓解症状，还能改善疾病预后。有多种可供处方的黏液活性药物，如何针对不同疾病正确选择这些药物对临床实践至关重要。到目前为止，尚无统一的共识或指南报道。一组中国呼吸内科医生共同努力，通过文献综述完成了本共识，总结了每种经典黏液活性药物的作用机制和用法。一般来说，抗氧化黏液活性药物在慢性气道疾病中发挥重要作用，包括但不限于气道黏液清除、减少急性加重和改善肺功能。
